CA2700468C - Procedes d'imagerie du niveau du transporteur de la dopamine - Google Patents

Procedes d'imagerie du niveau du transporteur de la dopamine Download PDF

Info

Publication number
CA2700468C
CA2700468C CA2700468A CA2700468A CA2700468C CA 2700468 C CA2700468 C CA 2700468C CA 2700468 A CA2700468 A CA 2700468A CA 2700468 A CA2700468 A CA 2700468A CA 2700468 C CA2700468 C CA 2700468C
Authority
CA
Canada
Prior art keywords
dopamine transporter
spect
subject
labeled
minutes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2700468A
Other languages
English (en)
Other versions
CA2700468A1 (fr
Inventor
Mark Hurtt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Andromedia Inc
Original Assignee
Harvard University
Alseres Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard University, Alseres Pharmaceuticals Inc filed Critical Harvard University
Publication of CA2700468A1 publication Critical patent/CA2700468A1/fr
Application granted granted Critical
Publication of CA2700468C publication Critical patent/CA2700468C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0446—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K51/0448—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil tropane or nortropane groups, e.g. cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nuclear Medicine (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne un procédé pour évaluer les niveaux du transporteur de la dopamine dans une zone sélectionnée du système nerveux central d'un sujet par imagerie SPECT, comprenant les étapes consistant à administrer une injection d'un ligand marqué du transporteur de la dopamine, approximativement au moment où le sujet est positionné pour une imagerie SPECT, et lancer une acquisition SPECT pour une durée d'environ 30 minutes en commençant environ 15 minutes après l'administration du ligand marqué du transporteur de la dopamine; et estimer, sur la base de ladite acquisition SPECT, la quantité de ligand marqué du transporteur de la dopamine qui se lie au transporteur de la dopamine.
CA2700468A 2007-10-31 2008-10-28 Procedes d'imagerie du niveau du transporteur de la dopamine Active CA2700468C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/931,979 US8084018B2 (en) 2007-10-31 2007-10-31 Methods for imaging dopamine transporter level
US11/931,979 2007-10-31
PCT/US2008/081419 WO2009058754A1 (fr) 2007-10-31 2008-10-28 Procédés d'imagerie du niveau du transporteur de la dopamine

Publications (2)

Publication Number Publication Date
CA2700468A1 CA2700468A1 (fr) 2009-05-07
CA2700468C true CA2700468C (fr) 2016-11-29

Family

ID=40583113

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2700468A Active CA2700468C (fr) 2007-10-31 2008-10-28 Procedes d'imagerie du niveau du transporteur de la dopamine

Country Status (5)

Country Link
US (1) US8084018B2 (fr)
EP (1) EP2219682B1 (fr)
JP (2) JP2011502130A (fr)
CA (1) CA2700468C (fr)
WO (1) WO2009058754A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1403328B1 (fr) 2002-09-26 2006-10-25 ILFORD Imaging Switzerland GmbH Colorants monoazoiques complexes de cuivre, leur préparation et leur utilisation
JP2011502966A (ja) * 2007-10-31 2011-01-27 アルセレス ファーマシューティカルズ， インコーポレイテッド ドーパミントランスポーターレベルを評価することによるレビー小体型認知症の診断およびレビー小体型認知症の処置のモニタリングのための方法
GB201313291D0 (en) * 2013-07-25 2013-09-11 Ge Healthcare Ltd Imaging neurological disease
JP5669118B1 (ja) * 2013-12-05 2015-02-12 独立行政法人国立循環器病研究センター 三次元脳状態画像解析装置
WO2016152448A1 (fr) * 2015-03-24 2016-09-29 日本メジフィジックス株式会社 Appareil de traitement d'image, procédé de traitement d'image et programme
WO2018148509A1 (fr) * 2017-02-10 2018-08-16 Likeminds, Inc. Méthodes de suivi in vivo de troubles dopaminergiques et de l'efficacité d'agents de traitement de ceux-ci
WO2020033523A1 (fr) * 2018-08-07 2020-02-13 Likeminds, Inc. Procédé de diagnostic de troubles dopaminergiques et du mouvement
WO2021102323A1 (fr) * 2019-11-21 2021-05-27 Likeminds, Inc. Unités d'emballage pharmaceutique et procédés d'administration concomitante de radiotraceurs
WO2022240817A1 (fr) * 2021-05-13 2022-11-17 Likeminds, Inc. Procédés de visualisation de transporteurs de dopamine

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506359A (en) 1992-08-24 1996-04-09 President And Fellows Of Harvard College Cocaine analogues and their use as cocaine drug therapies and therapeutic and imaging agents for neurodegenerative disorders
US5770180A (en) 1992-08-24 1998-06-23 Organix, Inc. Bridge-substituted tropanes for methods of imaging and therapy
US5493026A (en) 1993-10-25 1996-02-20 Organix, Inc. Substituted 2-carboxyalkyl-3-(fluorophenyl)-8-(3-halopropen-2-yl) nortropanes and their use as imaging for agents for neurodegenerative disorders
US6171576B1 (en) 1995-11-03 2001-01-09 Organix Inc. Dopamine transporter imaging agent
US7081238B2 (en) * 1995-11-03 2006-07-25 The President And Fellows Of Harvard College Methods for diagnosing and monitoring treatment ADHD by assessing the dopamine transporter level
US20020150535A1 (en) * 1995-11-03 2002-10-17 Madras Bertha K. Methods for diagnosing and monitoring treatment ADHD by assessing the dopamine transporter level
US5948933A (en) 1997-07-11 1999-09-07 Organix, Inc. Tropane analogs and methods for inhibition of monoamine transport
CA2285516C (fr) 1999-05-12 2010-12-07 President And Fellows Of Harvard College Agents d'imagerie pour transporteur de dopamine
US7553478B2 (en) * 1999-05-12 2009-06-30 President And Fellows Of Harvard College Methods for diagnosing and monitoring treatment ADHD by assessing the dopamine transporter level
US20100143248A1 (en) * 1999-06-28 2010-06-10 President And Fellows Of Harvard College Methods for diagnosing and monitoring treatment of adhd by assessing the dopamine transporter level

Also Published As

Publication number Publication date
US20090110635A1 (en) 2009-04-30
WO2009058754A1 (fr) 2009-05-07
US8084018B2 (en) 2011-12-27
CA2700468A1 (fr) 2009-05-07
JP2011502130A (ja) 2011-01-20
JP2014148529A (ja) 2014-08-21
EP2219682B1 (fr) 2018-07-18
EP2219682A1 (fr) 2010-08-25
EP2219682A4 (fr) 2012-11-14

Similar Documents

Publication Publication Date Title
CA2700468C (fr) Procedes d'imagerie du niveau du transporteur de la dopamine
Morbelli et al. EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0
Fischman et al. Rapid detection of Parkinson's disease by SPECT with altropane: a selective ligand for dopamine transporters
Holman et al. Muscarinic acetylcholine receptors in Alzheimer's disease: in vivo imaging with iodine 123—labeled 3-quinuclidinyl-4-Iodobenzilate and emission tomography
JP5603855B2 (ja) 神経変成疾患の放射性薬剤による画像化
Arlicot et al. Initial evaluation in healthy humans of [18F] DPA-714, a potential PET biomarker for neuroinflammation
US20100312105A1 (en) Methods for diagnosing and monitoring treatment of lewy body dementia by assessing dopamine transporter level
Kuikka et al. Pharmacokinetics and dosimetry of iodine-123 labelled PE2I in humans, a radioligand for dopamine transporter imaging
JP2011502966A5 (fr)
Fischman et al. SPECT imaging of dopamine transporter sites in normal and MPTP-treated rhesus monkeys
WO2018148509A1 (fr) Méthodes de suivi in vivo de troubles dopaminergiques et de l'efficacité d'agents de traitement de ceux-ci
US20210162078A1 (en) Method for diagnosis of dopaminergic and movement disorders
TWI520715B (zh) 雙同位素核醫造影方法
WO2021092096A1 (fr) Dosage individualisé de traceurs radioactifs pour imagerie
Gerson et al. Comparison of technetium-99m-Q3 and thallium-201 for detection of coronary artery disease in humans
Mountz et al. Basis and clinical application of brain imaging
Bradbury et al. Poster Abstracts from the Molecular Neuroimaging Symposium
Gerson et al. Comparison of Technetium-99m-Q3 and Thallium-201 for Detection of Coronary
JP2003503325A (ja) 注意欠陥多動性障害（ａｄ−ｈｄ）を決定するためのドーパミントランスポータの映像化

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20131017

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 16TH ANNIV.) - STANDARD

Year of fee payment: 16

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241023

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241023

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241023

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 17TH ANNIV.) - STANDARD

Year of fee payment: 17

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251023

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251023